Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis

References

• Hanchanale VS, Rao AR, Martin FL, Matanhelia SS. The unusual history and the urological applications of botulinum neurotoxin. Urol. Int. 85(2), 125–130 (2010).
   PubMedGoogle Scholar
• Kopera D. Botulinum toxin historical aspects: from food poisoning to pharmaceutical. Int. J. Dermatol. 50(8), 976–980 (2011).
   PubMed Web of Science ®Google Scholar
• Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J. Headache Pain 12(6), 593–601 (2011).
   PubMed Web of Science ®Google Scholar
• Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil. Rehabil. 29(23), 1761–1768 (2007).
   PubMed Web of Science ®Google Scholar
• Schurch B, Hodler J, Rodic B. Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections. J. Neurol. Neurosurg. Psychiatr. 63(4), 474–476 (1997).
   PubMedGoogle Scholar
• Jackson AB, Dijkers M, Devivo MJ, Poczatek RB. A demographic profile of new traumatic spinal cord injuries: change and stability over 30 years. Arch. Phys. Med. Rehabil. 85(11), 1740–1748 (2004).
   PubMed Web of Science ®Google Scholar
• van den Berg ME, Castellote JM, Mahillo-Fernandez I, de Pedro-Cuesta J. Incidence of spinal cord injury worldwide: a systematic review. Neuroepidemiology 34(3), 184–192; discussion 192 (2010).
   PubMed Web of Science ®Google Scholar
• Wyndaele M, Wyndaele JJ. Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey? Spinal Cord 44(9), 523–529 (2006).
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Chancellor MB, Blaivas JG. Bladder and sphincter behavior in patients with spinal cord lesions. J. Urol. 146(1), 113–117 (1991).
   PubMed Web of Science ®Google Scholar
• Anderson KD. Targeting recovery: priorities of the spinal cord-injured population. J. Neurotrauma 21(10), 1371–1383 (2004).
   PubMed Web of Science ®Google Scholar
• David BT, Steward O. Deficits in bladder function following spinal cord injury vary depending on the level of the injury. Exp. Neurol. 226(1), 128–135 (2010).
   PubMed Web of Science ®Google Scholar
• de Groat WC, Yoshimura N. Changes in afferent activity after spinal cord injury. Neurourol. Urodyn. 29(1), 63–76 (2010).
   PubMed Web of Science ®Google Scholar
• Blackmer J. Rehabilitation medicine: 1. Autonomic dysreflexia. CMAJ 169(9), 931–935 (2003).
   PubMed Web of Science ®Google Scholar
• Lindan R, Joiner E, Freehafer AA, Hazel C. Incidence and clinical features of autonomic dysreflexia in patients with spinal cord injury. Paraplegia 18(5), 285–292 (1980).
   PubMedGoogle Scholar
• Karlsson AK. Autonomic dysfunction in spinal cord injury: clinical presentation of symptoms and signs. Prog. Brain Res. 152, 1–8 (2006).
   PubMed Web of Science ®Google Scholar
• Pugliatti M, Rosati G, Carton H et al. The epidemiology of multiple sclerosis in Europe. Eur. J. Neurol. 13(7), 700–722 (2006).
   PubMed Web of Science ®Google Scholar
• Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338(5), 278–285 (1998).
   PubMed Web of Science ®Google Scholar
• Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol. Sci. 22(2), 117–139 (2001).
   PubMed Web of Science ®Google Scholar
• Araki I, Matsui M, Ozawa K, Takeda M, Kuno S. Relationship of bladder dysfunction to lesion site in multiple sclerosis. J. Urol. 169(4), 1384–1387 (2003).
   PubMed Web of Science ®Google Scholar
• Giannantoni A, Scivoletto G, Di Stasi SM, Grasso MG, Vespasiani G, Castellano V. Urological dysfunctions and upper urinary tract involvement in multiple sclerosis patients. Neurourol. Urodyn. 17(2), 89–98 (1998).
   PubMed Web of Science ®Google Scholar
• Koldewijn EL, Hommes OR, Lemmens WA, Debruyne FM, van Kerrebroeck PE. Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis. J. Urol. 154(1), 169–173 (1995).
   PubMed Web of Science ®Google Scholar
• Mehnert U, Birzele J, Reuter K, Schurch B. The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J. Urol. 184(3), 1011–1016 (2010).
   PubMed Web of Science ®Google Scholar
• Mahajan ST, Patel PB, Marrie RA. Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry. J. Urol. 183(4), 1432–1437 (2010).
   PubMed Web of Science ®Google Scholar
• Marrie RA, Horwitz RI, Cutter G, Tyry T, Vollmer T. Association between comorbidity and clinical characteristics of MS. Acta Neurol. Scand. 124(2), 135–141 (2011).
   PubMed Web of Science ®Google Scholar
• Jackson S. The patient with an overactive bladder – symptoms and quality-of-life issues. Urology 50(6A Suppl.), 18–22; discussion 23 (1997).
   PubMed Web of Science ®Google Scholar
• de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B; GENULF. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult. Scler. 13(7), 915–928 (2007).
   PubMed Web of Science ®Google Scholar
• Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 7(12), 1139–1151 (2008).
   PubMed Web of Science ®Google Scholar
• Freund P, Weiskopf N, Ward NS et al. Disability, atrophy and cortical reorganization following spinal cord injury. Brain 134(Pt 6), 1610–1622 (2011).
   PubMedGoogle Scholar
• Riccabona M, Koen M, Schindler M et al. Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J. Urol. 171(2 Pt 1), 845–848; discussion 848 (2004).
   PubMedGoogle Scholar
• Mahfouz W, Corcos J. Management of detrusor external sphincter dyssynergia in neurogenic bladder. Eur. J. Phys. Rehabil. Med. 47(4), 639–650 (2011).
   PubMed Web of Science ®Google Scholar
• Chen G, Liao L. Injections of botulinum toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury. Int. Urol. Nephrol. 43(3), 655–662 (2011).
   PubMedGoogle Scholar
• Sexton CC, Notte SM, Maroulis C et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int. J. Clin. Pract. 65(5), 567–585 (2011).
   PubMed Web of Science ®Google Scholar
• Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J. Manag. Care Pharm. 15(9), 728–740 (2009).
   PubMed Web of Science ®Google Scholar
• Cameron AP, Clemens JQ, Latini JM, McGuire EJ. Combination drug therapy improves compliance of the neurogenic bladder. J. Urol. 182(3), 1062–1067 (2009).
   PubMedGoogle Scholar
• Wein AJ. Voiding function and dysfunction, bladder physiology and pharmacology, and female urology: reply. J. Urol. 178(1), 353 (2007).
   Google Scholar
• Yamaguchi O, Nishizawa O, Takeda M et al.; Neurogenic Bladder Society. Clinical guidelines for overactive bladder. Int. J. Urol. 16(2), 126–142 (2009).
   PubMed Web of Science ®Google Scholar
• Bushman W, Steers WD, Meythaler JM. Voiding dysfunction in patients with spastic paraplegia: urodynamic evaluation and response to continuous intrathecal baclofen. Neurourol. Urodyn. 12(2), 163–170 (1993).
   PubMed Web of Science ®Google Scholar
• Bakke A, Malt UF. Social functioning and general well-being in patients treated with clean intermittent catheterization. J. Psychosom. Res. 37(4), 371–380 (1993).
   PubMed Web of Science ®Google Scholar
• Kessler TM, Ryu G, Burkhard FC. Clean intermittent self-catheterization: a burden for the patient? Neurourol. Urodyn. 28(1), 18–21 (2009).
   PubMed Web of Science ®Google Scholar
• Lindehall B, Abrahamsson K, Hjälmås K, Jodal U, Olsson I, Sillén U. Complications of clean intermittent catheterization in boys and young males with neurogenic bladder dysfunction. J. Urol. 172(4 Pt 2), 1686–1688 (2004).
   PubMed Web of Science ®Google Scholar
• Groah SL, Weitzenkamp DA, Lammertse DP, Whiteneck GG, Lezotte DC, Hamman RF. Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer. Arch. Phys. Med. Rehabil. 83(3), 346–351 (2002).
   PubMed Web of Science ®Google Scholar
• Greenwell TJ, Venn SN, Mundy AR. Augmentation cystoplasty. BJU Int. 88(6), 511–525 (2001).
   PubMed Web of Science ®Google Scholar
• Harper M, Popat RB, Dasgupta R, Fowler CJ, Dasgupta P. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int. 92(3), 325–326 (2003).
   PubMedGoogle Scholar
• Abdel-Meguid TA. Botulinum toxin-A injections into neurogenic overactive bladder – to include or exclude the trigone? A prospective, randomized, controlled trial. J. Urol. 184(6), 2423–2428 (2010).
   PubMed Web of Science ®Google Scholar
• Mascarenhas F, Cocuzza M, Gomes CM, Leão N. Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients. Neurourol. Urodyn. 27(4), 311–314 (2008).
   PubMed Web of Science ®Google Scholar
• Apostolidis A, Dasgupta P, Denys P et al.; European Consensus Panel. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur. Urol. 55(1), 100–119 (2009).
   PubMed Web of Science ®Google Scholar
• Mangera A, Andersson KE, Apostolidis A et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur. Urol. 60(4), 784–795 (2011).
   PubMed Web of Science ®Google Scholar
• Wöllner J, Kessler TM. Botulinum toxin injections into the detrusor. BJU Int. 108(9), 1528–1537 (2011).
   PubMedGoogle Scholar
• Jahn R. Neuroscience. A neuronal receptor for botulinum toxin. Science 312(5773), 540–541 (2006).
   PubMedGoogle Scholar
• Chancellor MB, Fowler CJ, Apostolidis A et al. Drug insight: biological effects of botulinum toxin A in the lower urinary tract. Nat. Clin. Pract. Urol. 5(6), 319–328 (2008).
   PubMedGoogle Scholar
• Hanna-Mitchell AT, Birder LA. New insights into the pharmacology of the bladder. Curr. Opin. Urol. 18(4), 347–352 (2008).
   PubMedGoogle Scholar
• Kanai A, Wyndaele JJ, Andersson KE et al. Researching bladder afferents – determining the effects of b(3)-adrenergic receptor agonists and botulinum toxin type-A. Neurourol. Urodyn. 30(5), 684–691 (2011).
   PubMed Web of Science ®Google Scholar
• Smith CP, Gangitano DA, Munoz A et al. Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Neurochem. Int. 52(6), 1068–1075 (2008).
   PubMed Web of Science ®Google Scholar
• Schurch B, de Sèze M, Denys P et al.; Botox Detrusor Hyperreflexia Study Team. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J. Urol. 174(1), 196–200 (2005).
   PubMed Web of Science ®Google Scholar
• Cruz F, Herschorn S, Aliotta P et al. Efficacy and safety of onabotulinum toxin A in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur. Urol. 60(4), 742–750 (2011).
   PubMed Web of Science ®Google Scholar
• Ginsberg D, Gousse A, Keppenne V et al. Phase 3 efficacy and tolerability study of onabotulinum toxin A for urinary incontinence from neurogenic detrusor overactivity. J. Urol. 187(6), 2131–2139 (2012).
   PubMed Web of Science ®Google Scholar
• Schulte-Baukloh H, Michael T, Schobert J, Stolze T, Knispel HH. Efficacy of botulinum – a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 59(3), 325–327; discussion 327 (2002).
   PubMed Web of Science ®Google Scholar
• Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol. Urodyn. 24(3), 231–236 (2005).
   PubMed Web of Science ®Google Scholar
• Reitz A, Schurch B. Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity. J. Urol. 171(2 Pt 1), 804–805 (2004).
   PubMedGoogle Scholar
• Pannek J, Göcking K, Bersch U. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction. BJU Int. 104(9), 1246–1250 (2009).
   PubMed Web of Science ®Google Scholar
• Reitz A, Denys P, Fermanian C, Schurch B, Comperat E, Chartier-Kastler E. Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur. Urol. 52(6), 1729–1735 (2007).
   PubMed Web of Science ®Google Scholar
• Mouttalib S, Khan S, Castel-Lacanal E et al. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment. BJU Int. 106(11), 1677–1680 (2010).
   PubMed Web of Science ®Google Scholar
• Bootsma AM, Laguna Pes MP, Geerlings SE, Goossens A. Antibiotic prophylaxis in urologic procedures: a systematic review. Eur. Urol. 54(6), 1270–1286 (2008).
   PubMed Web of Science ®Google Scholar
• Gamé X, Castel-Lacanal E, Bentaleb Y et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur. Urol. 53(3), 613–618 (2008).
   PubMed Web of Science ®Google Scholar
• Courtois F, Caremel R, Charvier K, Ruffion A, Journel NM. Botox treatment and its impact on ejaculation and fertility in men with spinal cord injury. J. Sex. Med. 7, 431 (2010).
   Google Scholar
• Bakheit AM, Liptrot A, Newton R, Pickett AM. The effect of total cumulative dose, number of treatment cycles, interval between injections, and length of treatment on the frequency of occurrence of antibodies to botulinum toxin type A in the treatment of muscle spasticity. Int. J. Rehabil. Res. 35(1), 36–39 (2012).
   PubMedGoogle Scholar
• Naumann M, Carruthers A, Carruthers J et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov. Disord. 25(13), 2211–2218 (2010).
   PubMed Web of Science ®Google Scholar
• Reitz A, Stöhrer M, Kramer G et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur. Urol. 45(4), 510–515 (2004).
   PubMed Web of Science ®Google Scholar
• De Laet K, Wyndaele JJ. Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord 43(7), 397–399 (2005).
   PubMed Web of Science ®Google Scholar
• Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch. Phys. Med. Rehabil. 71(1), 24–26 (1990).
   PubMed Web of Science ®Google Scholar
• Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J. Urol. 155(3), 1023–1029 (1996).
   PubMedGoogle Scholar
• Patti F. Cognitive impairment in multiple sclerosis. Mult. Scler. 15(1), 2–8 (2009).
   PubMed Web of Science ®Google Scholar
• Vahter L, Zopp I, Kreegipuu M, Kool P, Talvik T, Gross-Paju K. Clean intermittent self-catheterization in persons with multiple sclerosis: the influence of cognitive dysfunction. Mult. Scler. 15(3), 379–384 (2009).
   PubMedGoogle Scholar
• Asayama K, Kihara K, Shidoh T, Shigaki M, Ikeda T. The functional limitations of tetraplegic hands for intermittent clean self-catheterisation. Paraplegia 33(1), 30–33 (1995).
   PubMedGoogle Scholar
• Kiyono Y, Hashizume C, Ohtsuka K, Igawa Y. Improvement of urological-management abilities in individuals with tetraplegia by reconstructive hand surgery. Spinal Cord 38(9), 541–545 (2000).
   PubMedGoogle Scholar
• Hori S, Patki P, Attar KH, Ismail S, Vasconcelos JC, Shah PJ. Patients’ perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury. BJU Int. 104(2), 216–220 (2009).
   PubMed Web of Science ®Google Scholar
• Khan S, Game X, Kalsi V et al. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J. Urol. 185(4), 1344–1349 (2011).
   PubMedGoogle Scholar
• Kuo HC. Prostate botulinum A toxin injection – an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 65(4), 670–674 (2005).
   PubMed Web of Science ®Google Scholar